<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306731</url>
  </required_header>
  <id_info>
    <org_study_id>College of Medicine</org_study_id>
    <nct_id>NCT04306731</nct_id>
  </id_info>
  <brief_title>Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Use of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sulaimani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sulaimani</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates nanotechnology structured water magnalife in urology and to test its
      effects against lower urinary tract infections (UTI) in females.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study represents the first time to use nanotechnology structured water magnalife in
      urology and to test its effects against lower urinary tract infections (UTI) in females.
      Urinary tract infection (UTI ) is the second most common bacterial infection, affecting women
      at a much higher frequency than men. There is a higher rate of recurrence of UTI, and a
      recurrent infection will follow 25-35% of initial UTI episodes within 3-6 months.

      Intermittent or prolonged low dose antibiotic therapy has been used to treat and prevent
      recurrent UTI. Emerging of resistance to antimicrobial agents, enormous economic burden, and
      the side effects of antibiotics have led to the search for an alternative non-antibiotic
      prophylaxis of recurrent UTI. Nanotechnology structured water is a new type of drinking water
      that has been prepared using different types of energy fields and electromagnetic fields to
      produce this structured water, which has new and different characteristics from the ordinary
      water.

      In the current study, the efficacy of nanotechnology structured water magnalife was compared
      with low-dose Trimethoprim and bottled drinking water for the prevention of recurrent UTI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2014</start_date>
  <completion_date type="Actual">April 21, 2017</completion_date>
  <primary_completion_date type="Actual">April 21, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Urinary Tract Infection</measure>
    <time_frame>Twelve months</time_frame>
    <description>Urinalysis by GUE (&gt;10 white blood cells (WBC)/mm3 per high-power field (HPF) Urine culture (urinary pathogen of ≥105 colony-forming units (CFU) per mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first recurrent UTI</measure>
    <time_frame>Twelve months</time_frame>
    <description>The time since the beginning of the study until the first recurrent UTI (days)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">437</enrollment>
  <condition>Recurrent Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Interventional (Group M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group of patients given nanotechnology structured water magnalife</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (Group T)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The group of patients given Trimethoprim</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Group O)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The group of patients given ordinary bottled drinking water</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nanotechnology Structured water Magnalife</intervention_name>
    <description>Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules</description>
    <arm_group_label>Interventional (Group M)</arm_group_label>
    <other_name>Magnalife</other_name>
    <other_name>5200250040466</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Control (Group T)</arm_group_label>
    <other_name>Proloprim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ordinary bottled drinking water</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo (Group O)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 2 (two or more than two) UTI in the last 6 months

          -  ≥ 3 (three or more than three) UTI in the last 12 months

        Exclusion Criteria:

          -  immunotherapy

          -  radiotherapy

          -  malignancy

          -  steroids

          -  chronic infections

          -  chemotherapy

          -  immunosuppressive drugs

          -  anatomical abnormality of the urinary tract

          -  surgical operation the urinary tract
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali K M.Sami, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>College of Medicine, University of Sulaimani</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>College of Medicine, University of Sulaimani</name>
      <address>
        <city>Sulaymaniyah</city>
        <state>Kurdistan Region</state>
        <zip>00964</zip>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sulaimani</investigator_affiliation>
    <investigator_full_name>ALI KAMAL M. SAMI</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>nanotechnology water, antibiotic prophylaxis, recurrent UTI.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The duration of illness, number of recurrence of UTI, other co-morbid diseases</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

